Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousFederal Circuit Affirms District Court?s Extension of 30-Month FDA Stay
By Dennis Crouch, Esq.
Eli Lilly v. Teva Pharmaceuticals (Fed. Cir. 2009)
Teva is hoping to make a generic version of Lilly's Evista brand raloxifene tablets that are used to help prevent postmenopausal osteoporosis. In May 2006, Teva filed an abbreviated new drug agreement (ANDA) and Lilly subsequently sued for patent infringement and to block the generic release. Under the law, after the patentee files suit, the FDA cannot then approve the generic for thirty months "unless the court has extended or reduced the period because of a failure of either [party] to cooperate reasonably in expediting the action." This is commonly known as the "thirty month stay."
In this case, the court originally set a trial date four months after the end of the thirty month period. In the months leading up to trial Teva altered its proposed generic formulation, which changed Lilly's litigation strategy. As a result, the district court ordered that the FDA thirty month stay be extended for four extra months ? until May 2009. Teva filed an emergency appeal to lift the stay.
On appeal, a split Federal Circuit panel affirmed ? finding that the district court acted within its discretion in extending the stay based on Teva's activity. "Trial courts, thus, may shorten or extend the thirty-month statutory period based on the parties' uncooperative discovery practices before the court." In its decision, the court distinguished the 2002 Andrx v. Bioval case. In Andrx, the Federal Circuit found that the district court had abused its discretion in shortening a thirty-month stay based on a party's "positions before the FDA." Rather, changes to the thirty-month period must be based on failure to cooperate court.
In dissent, Judge Prost argued that the majority misinterpreted the statute to grant too much deference to the district court in extending the stay. Rather, the statute requires that the stay should only be extended when a party fails "to cooperate reasonably in expediting the action." Here, Judge Prost argues, the lower court did not find that Teva failed to cooperate, but only that Lilly could use more time to respond. The statute is limited in a way that does not allow extension of the stay in that situation.
Notes:
- Judge Rader wrote the majority opinion and was joined by Chief Judge Michel.
- On the expedited schedule, Appellant filed its principle brief November 24, 2008; briefing was complete on December 30, 2008; Oral arguments were heard on January 14, 2009; and a decision rendered on February 24, 2009.
Full post as published by Patently Obvious on February 24, 2009 (boomark / email).
How to Stop Home Foreclosure
Bankruptcy can Stop Foreclosure
Selection of State Supreme Court Judges
How State Court Judges are Selected
Law Enforcement and Criminal Justice Career Choices
Descriptions of law enforcement occupations
Privacy Protection Act 42 USC 21A
Federal Newsroom Law
California Supreme Court Proposition 8 Decision
Court Rejects Challenges to Proposition 8, but Finds Marriages Valid
Federal Adoption Tax Credit
Financial Incentive for Adoptive Parents
Rutland School District
Double pay offered as part of class action wage dispute settlement, pending court approval.
Medical Records
To Stay out of Pharma's Hands
Specialty Lamp International
Recalls Counterfeit Circuit Breakers
Folding Soccer Goals Recalled
20-Month Old Child Found Strangled to Death
Richard Mellon Scaife
Billionaire divorce lawsuit ends in a $725,000 a month settlement.
Ebay Fined
French Court Sets Fine at $61 Million

Federal Circuit Affirms Extension of 30-Month Stay Against Teva's Generic Evista
Grant of stay while preliminary injunction motion pending abuse of discretion
Second Circuit Affirms Difficult Choice with Race-Conscious Effect
8th Circuit Affirms Dismissal of Religious Challenge To Controlled Substances Acts
Whats Two Extra Weeks Of Exclusivity for Evista® Worth A Lot.







